Enzon Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Enzon Pharmaceuticals generated cash of $1,305,000, which is more than the previous year. Cash used in financing activities reached the amount of -$1,275,000 last year. Net change in cash is therefore $30,000.
Cash Flow
| 2014 | 32.33M | 151K | -4.44M |
|---|---|---|---|
| 2015 | 14.67M | 0 | -37.56M |
| 2016 | 2.59M | 0 | -6.63M |
| 2017 | 6.47M | 0 | -6.63M |
| 2018 | -978K | 0 | 0 |
| 2019 | 6.90M | 0 | -7.95M |
| 2020 | -380K | 0 | 43.07M |
| 2021 | -501K | 0 | -2.02M |
| 2022 | -659K | 0 | -1.27M |
| 2023 | 1.30M | 0 | -1.27M |
ENZN Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 46.98M | 47.64M | 48.14M | 5.44M | 6.5M | 7.47M | 7.63M | 11.67M | 34.56M | 6.52M |
Operating activities | ||||||||||
Net income | 1.37M | -186K | -469K | -1.31M | -979K | 5.84M | 5.44M | -1.12M | 21.63M | 28.79M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6K | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6K | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 28K | -23K | -28K | 7M | -7M | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 23K | 28K | -7M | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 0 | 29K | -22K | -115K | 214K | -545K | 680K | -91K | 88K |
Cash generated by operating activities | 1.30M | -659K | -501K | -380K | 6.90M | -978K | 6.47M | 2.59M | 14.67M | 32.33M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 151K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 43.6M | 0 | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | -1.27M | -1.27M | 0 | 0 | -7.95M | 0 | -6.63M | -6.63M | -37.56M | -4.41M |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6K | -30K |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | -1.27M | -1.27M | -2.02M | 43.07M | -7.95M | 0 | -6.63M | -6.63M | -37.56M | -4.44M |
Net Change In Cash | 30K | -659K | -501K | 42.69M | -1.05M | -978K | -161K | -4.03M | -22.89M | 28.04M |
Cash at end of period | 47.01M | 46.98M | 47.64M | 48.14M | 5.44M | 6.5M | 7.47M | 7.63M | 11.67M | 34.56M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |